MAPT and dementia: Research investigating plasma (p-tau181, p-tau217, and p-tau231) and PET imaging (18F-RO948, 18F-MK-6240, and 18F-flortaucipir) T biomarkers has generally detected an increasing tau burden from the preclinical stage to clinically overt dementia.